|Issuer:||VAXART, INC. (VXRT)|
|Original Submission Date:|
WHEADON DAVID E.
C/O VAXART, INC.
170 HARBOR WAY, SUITE 300 SOUTH SAN FRANCISCO, CA 94080
|Title of Security||Transaction Date||2a. Deemed Execution Date||Transaction Code||Shares||Acquired or Disposed||Price per share||5. Amount of Securities Beneficially Owned Following Reported Transaction||6. Ownership Form Direct or Indirect||Nature of Indirect Ownership|
|Title of Derivative Security||Conversion or Exercise Price of Derivative Security||Transaction Date||Deemed Execution Date||Transaction Code||Number of Derivative Securities Acquired (A) or Disposed of (D)||Date Exercisable||Expiration Date||Title and Amount of Securities Underlying Derivative Security||Price of Derivative Security||Number of derivative Securities Beneficially Owned Following Reported Transaction(s)||Ownership Form: Direct (D) or Indirect (I)||Nature of Indirect Beneficial Ownership|
|STOCK OPTION (RIGHT TO BUY)||6.54||2021-06-16||deemed execution date||A||65,700 (a)||2031-05-09||common stock 65,700||$6.54||65,700||direct|
|f1||the option was granted by the board of directors of vaxart, inc. effective on may 10, 2021, subject to stockholder approval of an amendment to the vaxart, inc. 2019 equity incentive plan, under which the stock option was granted. vaxart, inc.'s stockholders approved the plan amendment on june 16, 2021.|
|f2||the shares subject to this option shall vest annually over three years from the vesting commencement date of april 21, 2021, the date of the grantee's appointment as a director of vaxart, inc.|